Search

Displaying results 8701 - 8710 of 10000 in total
  1. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.

    Mixtures: biclora-D, biclora-DInternational brands: Di-Paralene
  2. Drug

    RD06-04

    go.drugbank.com/drugs/DB24647
    Investigational

    RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).

  3. Drug

    PX-12

    go.drugbank.com/drugs/DB05448
    Investigational

    methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits tumor growth in … Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced

  4. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests.

  5. Drug

    OM85

    go.drugbank.com/drugs/DB16533
    Investigational

    OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.

  6. Drug

    MG98

    go.drugbank.com/drugs/DB06544
    Experimental

    MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.

  7. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility

  8. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

  9. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  10. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal is a schedule III drug in the U.S.